Kalmar Investments Inc. DE cut its position in The Cooper Cos. (NYSE:COO) by 25.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 236,731 shares of the medical device company’s stock after selling 81,290 shares during the period. The Cooper Cos. makes up about 1.8% of Kalmar Investments Inc. DE’s investment portfolio, making the stock its 8th largest position. Kalmar Investments Inc. DE owned approximately 0.49% of The Cooper Cos. worth $40,616,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Sumitomo Mitsui Asset Management Company LTD raised its stake in shares of The Cooper Cos. by 1.5% in the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 3,331 shares of the medical device company’s stock worth $571,000 after buying an additional 49 shares during the last quarter. ClariVest Asset Management LLC bought a new position in The Cooper Cos. during the second quarter valued at approximately $24,579,000. Intermede Investment Partners Ltd increased its position in The Cooper Cos. by 2.1% in the second quarter. Intermede Investment Partners Ltd now owns 129,693 shares of the medical device company’s stock valued at $22,251,000 after buying an additional 2,633 shares during the period. Retirement Systems of Alabama increased its position in The Cooper Cos. by 2.9% in the second quarter. Retirement Systems of Alabama now owns 129,395 shares of the medical device company’s stock valued at $22,200,000 after buying an additional 3,697 shares during the period. Finally, Diversified Trust Co increased its position in The Cooper Cos. by 5.9% in the second quarter. Diversified Trust Co now owns 1,800 shares of the medical device company’s stock valued at $309,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 98.76% of the company’s stock.

Institutional Ownership by Quarter for The Cooper Cos. (NYSE:COO)

Shares of The Cooper Cos. (NYSE:COO) traded up 1.31% during mid-day trading on Tuesday, reaching $180.68. 391,585 shares of the company’s stock traded hands. The Cooper Cos. has a 12-month low of $119.28 and a 12-month high of $190.99. The company’s 50-day moving average price is $182.83 and its 200-day moving average price is $171.69. The stock has a market capitalization of $8.81 billion, a PE ratio of 35.38 and a beta of 0.29.

The Cooper Cos. (NYSE:COO) last released its quarterly earnings data on Thursday, September 1st. The medical device company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.29 by $0.01. The Cooper Cos. had a net margin of 13.14% and a return on equity of 14.89%. The company earned $514.70 million during the quarter. During the same period in the previous year, the firm posted $1.97 EPS. The firm’s quarterly revenue was up 11.5% on a year-over-year basis. Analysts anticipate that The Cooper Cos. will post $8.43 earnings per share for the current year.

Several research analysts have commented on the stock. KeyCorp set a $221.00 price objective on shares of The Cooper Cos. and gave the company a “buy” rating in a report on Saturday, October 1st. JPMorgan Chase & Co. assumed coverage on shares of The Cooper Cos. in a report on Wednesday, July 13th. They set a “buy” rating for the company. Robert W. Baird increased their price objective on shares of The Cooper Cos. from $185.00 to $196.00 and gave the company an “outperform” rating in a report on Thursday, August 18th. Stifel Nicolaus increased their price objective on shares of The Cooper Cos. from $180.00 to $195.00 and gave the company a “buy” rating in a report on Thursday, June 30th. Finally, Wells Fargo & Co. reissued a “hold” rating on shares of The Cooper Cos. in a report on Sunday, September 11th. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $187.40.

In related news, Director William A. Kozy bought 270 shares of the business’s stock in a transaction dated Tuesday, September 6th. The stock was acquired at an average price of $186.69 per share, with a total value of $50,406.30. Following the completion of the purchase, the director now directly owns 770 shares of the company’s stock, valued at $143,751.30. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Albert G. White III sold 20,000 shares of the business’s stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $185.72, for a total transaction of $3,714,400.00. Following the sale, the executive vice president now directly owns 41,639 shares of the company’s stock, valued at approximately $7,733,195.08. The disclosure for this sale can be found here. Insiders own 2.20% of the company’s stock.

The Cooper Cos. Company Profile

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

5 Day Chart for NYSE:COO

Receive News & Stock Ratings for The Cooper Cos. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Cooper Cos. and related stocks with our FREE daily email newsletter.